585 related articles for article (PubMed ID: 29309751)
1. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
2. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Effects of Anthocyanins and Environmental Enrichment in R6/1 Huntington's Disease Mice.
Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
J Huntingtons Dis; 2016 Oct; 5(3):285-296. PubMed ID: 27567888
[TBL] [Abstract][Full Text] [Related]
4. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
[TBL] [Abstract][Full Text] [Related]
5. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.
Gharami K; Xie Y; An JJ; Tonegawa S; Xu B
J Neurochem; 2008 Apr; 105(2):369-79. PubMed ID: 18086127
[TBL] [Abstract][Full Text] [Related]
6. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease.
Decressac M; Wright B; Tyers P; Gaillard A; Barker RA
Exp Neurol; 2010 Nov; 226(1):24-32. PubMed ID: 20673761
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease.
Di Pardo A; Castaldo S; Amico E; Pepe G; Marracino F; Capocci L; Giovannelli A; Madonna M; van Bergeijk J; Buttari F; van der Kam E; Maglione V
Hum Mol Genet; 2018 Jul; 27(14):2490-2501. PubMed ID: 29688337
[TBL] [Abstract][Full Text] [Related]
8. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
[TBL] [Abstract][Full Text] [Related]
9. Effects of Exogenous NUB1 Expression in the Striatum of HDQ175/Q7 Mice.
Vodicka P; Chase K; Iuliano M; Valentine DT; Sapp E; Lu B; Kegel-Gleason KB; Sena-Esteves M; Aronin N; DiFiglia M
J Huntingtons Dis; 2016 Jun; 5(2):163-74. PubMed ID: 27314618
[TBL] [Abstract][Full Text] [Related]
10. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
Dufour BD; McBride JL
Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
[TBL] [Abstract][Full Text] [Related]
11. Exposure of R6/2 mice in an enriched environment augments P42 therapy efficacy on Huntington's disease progression.
Couly S; Carles A; Denus M; Benigno-Anton L; Maschat F; Maurice T
Neuropharmacology; 2021 Mar; 186():108467. PubMed ID: 33516737
[TBL] [Abstract][Full Text] [Related]
12. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.
Squitieri F; Di Pardo A; Favellato M; Amico E; Maglione V; Frati L
J Cell Mol Med; 2015 Nov; 19(11):2540-8. PubMed ID: 26094900
[TBL] [Abstract][Full Text] [Related]
13. Disease-modifying effects of ganglioside GM1 in Huntington's disease models.
Alpaugh M; Galleguillos D; Forero J; Morales LC; Lackey SW; Kar P; Di Pardo A; Holt A; Kerr BJ; Todd KG; Baker GB; Fouad K; Sipione S
EMBO Mol Med; 2017 Nov; 9(11):1537-1557. PubMed ID: 28993428
[TBL] [Abstract][Full Text] [Related]
14. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
[TBL] [Abstract][Full Text] [Related]
15. Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease.
El-Akabawy G; Rattray I; Johansson SM; Gale R; Bates G; Modo M
BMC Neurosci; 2012 Aug; 13():97. PubMed ID: 22876937
[TBL] [Abstract][Full Text] [Related]
16. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
Reick C; Ellrichmann G; Tsai T; Lee DH; Wiese S; Gold R; Saft C; Linker RA
Exp Neurol; 2016 Nov; 285(Pt A):12-23. PubMed ID: 27587303
[TBL] [Abstract][Full Text] [Related]
17. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
[TBL] [Abstract][Full Text] [Related]
18. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease.
Linares GR; Chiu CT; Scheuing L; Leng Y; Liao HM; Maric D; Chuang DM
Exp Neurol; 2016 Jul; 281():81-92. PubMed ID: 27085395
[TBL] [Abstract][Full Text] [Related]
19. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.
Simmons DA; Belichenko NP; Yang T; Condon C; Monbureau M; Shamloo M; Jing D; Massa SM; Longo FM
J Neurosci; 2013 Nov; 33(48):18712-27. PubMed ID: 24285878
[TBL] [Abstract][Full Text] [Related]
20. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
